ZBD | $40,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Asymmetric Security | $4,200,000 | (Jan 23, 2026)
Certified by Founder
Lodge
ImmunoScape
start up
Singapore
- Singapore
- 26/09/2022
- Unknown
- $14,000,000
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic.
To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.
- Industry Biotechnology Research
- Website https://immunoscape.com/
- LinkedIn https://www.linkedin.com/company/immunoscape/
Related People
Choon-Peng (Choon) NgFounder
Singapore -
Singapore
General Management. Cross functional and cross geography experience.
Cubby | $63,000,000 | (Jan 23, 2026)
Cambio | $18,000,000 | (Jan 23, 2026)
Cork Protocol | $5,500,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)
Mendra | $82,000,000 | (Jan 23, 2026)
Artie Technologies | $12,000,000 | (Jan 23, 2026)
Antidote Legal | $5,000,000 | (Jan 23, 2026)
One to One Health | $12,000,000 | (Jan 22, 2026)